Current Issues of Pharmacy and Medical Sciences

Association between concentration of melatonin, and lipoproteins, LPO, hsCRP, NTproBNP in chronic heart failure patients

Curr Issues Pharm Med Sci., Vol. 27, No. 3, Pages 159-164

Elżbieta Kimak1, Grzegorz Dzida2, Dariusz Duma1, Andrzej Prystupa2, Magdalena Hałabiś1, Aleksandra Kimak3,
Bartosz Zięba1, Iwona Kaznowska-Bystrek1, Agnieszka Kowalska 1

1 Department of Laboratory Diagnostics, Medical University of Lublin

2Department of Internal Diseases, Medical University of Lublin

3Chair and Department of Conservative Dentistry with Endodontics, Medical University of Lublin 


DOI: 10.1515/cipms-2015-0007

Abstract

The aim of the study was to examine concentrations and relationships between melatonin levels assessed at 0:200 hrs and 0:700 hrs, lipid hydroperoxide (LPO) assessed at 0:200 hrs and 0:700 hrs, and apolipoprotein (apo)AI, apoAII, apoB, high sensitivity C-reactive protein (hsCRP) and NT-proBNP, in 27 patients with chronic heart failure (CHF) (17 patients – with NYHA class II and 10 – with NYHA class III). In the study, Lipoproteins apoAI, apoAII, apoB, high sensitivity C-reactive protein (hsCRP) levels were determined by way of immunonephelometric methods, serum melatonin concentration was measured by using a competitive enzyme immunoassay technique, while serum LPO concentration was measured by using Cayman’s Lipid Hydroperoxide Assay Kit. In the study, CHF patients without acute inflammatory response demonstrated a decreased concentration of high density lipoprotein cholesterol (HDL-C), apoAI, apoAII levels, but an increased concentration of NT-proBNP, hsCRP and LPO at night, and LPO at daytime; however, the concentration of LPO at 0:700 was lower than at 0:200. Pearson’s correlation test and multiple ridge stepwise regression showed that melatonin administered at night exerts an effect on the composition of apoAI and apoAII of HDL particles, and induces decreased LPO at 0:700, but has no effect upon NT-proBNP levels in patients with NYHA class II.
However, in patients with NYHA class III, melatonin administered at night induces an increase in the content of apoAII and apoAI, which further decreases hsCRP, and this, together with the administered melatonin, brings about daytime decreases in NT-proBNP and hsCRP levels. The results indicated that the content of apoAII and apoAI in HDL particles and melatonin demonstrate an anti-oxidative and anti-inflammatory effect, and together, have a cardio-protective effect on patients with advanced CHF. Hence, the results support melatonin being a cardio-protective agent. These relationships, however, need to be confirmed in further studies.
 

Keywords

hsCRP, melatonin, oxidative stress, chronic heart failure.

References

  1. Aqil A., Reiter R.J., Jimenez-Aranda A., Iban-Arias R., Navarro-Alarcon M., Adem A., Fernandez-Vazquez G. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J. Pineal Res., 54, 381, 2013.
  2. Berrougui H., Claudia N. Momo CN., Khalil A.: Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J. Clin. Lipidol. 6, 524, 2012.
  3. Birjmohun R.S., Dallinga-Thie G.M., Kuivenhoven J.A., et al.: Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation, 116, 2029, 2007.
  4. Dominguez-Rodriguez A.: Melatonin in cardiovascular disease. Expert. Opin. Investig., 21, 1593, 2012.
  5. Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzas P.: The role of melatonin in acute myocardial infarction. Front. Biosci., 17, 2433, 2012.
  6. Dzida G., Prystupa A., Lachowska-Kotowska P., Kardas T., Kamieński P., Kimak E., Hałabiś M., Kiciński P.: Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure. AAEM., 20, 745, 2013.
  7. Espino J., Pariente JA., Rodriguez A.B.: Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxidative Med. Cell. Longev., 2012, 6702941, 9p, 2012.
  8. Friedewald W.T., Levy R.I., Friedrickson D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem., 18, 499, 1972.
  9. Gauthamadasa K., Vaitinadin N.S., Dressman J.L., Macha S., Homan R., Greis K.D., Silva G.D.: Apolipoprotein AII-mediated conformation changes of apolipoprotein AI in discoidal high density lipoproteins. J. Biol. Chem., 287, 7615, 2012.
  10. Kimak E., Bylina J., Solski J., Hałabiś M., Baranowicz-Gąszczyk I., Książek A. Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients. CBB., 67, 695, 2013.
  11. Kimak E., Hałabiś M., Baranowicz-Gąszczyk I., Solski J., Książek A.: Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients. JZUS-B., 12, 365, 2011.
  12. Korkmaz A., Reiter R.J., Topal T., Manchester L.C., Oter S., Tan D.X.: Melatonin, an established antioxidant worthy of use in clinical trials. Mol. Med., 15, 43, 2009.
  13. Maïga S.F., Kalopissis A-D., Chabert M.: Apolipoprotein AII is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie., 96, 56, 2014.
  14. Marchetti C., Sidahmed-Adrar N., Collin F., Jore D., Garde`s-Albert M., Bonnefont-Rousselot D.: Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J. Pineal. Res., 51, 286, 2011.
  15. Morceli G., Honorio-Franca A.C., Fagundes D.L., Calderon I.M., Franca E.L.: Antioxidant effect of melatonin on the functional activity of colostral phagocytes in diabetic women. PloSOne 8, e56915. Epub 2013.
  16. Mozaffari S., Hasani-Ranjbar S., Abdollahi M.: The mechanisms of positive effects of melatonin in dyslipidemia: a systemic review of animal and human studies. Int. J. Pharmacol., 8, 496, 2012.
  17. Ng T.W.K., Chan D.C., Hugh P., Barrett R., Watts G.F.: Effect of weight loss on HDL-apoAII kinetics in the metabolic syndrome. Clin. Sci., 118, 79, 2010.
  18. Papaharlambus C.A , Griendling K.K.: Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med., 17, 48, 2007.
  19. Podrez E. A.: Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin. Exp. Pharmacol. Physiol., 37, 719, 2010.
  20. Reiter R. J., Tan D-X., Paredes S.D.: Beneficial effects of melatonin in cardiovascular disease. Ann. Med., 42, 276, 2010.
  21. Shuhei N., Söderlund S., Jauhiainen M., Taskinen M-R.: Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipid Health Dis., 9, 104, 2010.
  22. Tamura H., Nakamura Y., Narimatsu A., Yamagata Y., Takasaki A., Reiter R.J.: Melatonin treatment in peri- and postmenopausal women elevates serum high density lipoprotein cholesterol levels without influencing total cholesterol levels. J. Pineal. Res., 45, 101, 2008.
  23. Wakatsuki A., Okatani Y., Ikenoue N., Shinohara K., Watanabe K., Fukaya T.: Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J. Pineal Res., 3,: 281, 2001.
  24. Wu W.S., Chou M.T., Chao C.M., Chang C.K., Lin M.T., Chang C.P.: Melatonin reduces acute lung inflammation, edema, and hemorrhage in heatstroke rats. Acta Pharmacol. Sin., 33, 775, 2012.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30